| Item Type | Name |
|
Concept
|
Protein-Tyrosine Kinases
|
|
Concept
|
Receptor Protein-Tyrosine Kinases
|
|
Concept
|
Class I Phosphatidylinositol 3-Kinases
|
|
Concept
|
Phosphatidylinositol 3-Kinases
|
|
Concept
|
Extracellular Signal-Regulated MAP Kinases
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Academic Article
|
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
|
|
Academic Article
|
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.
|
|
Academic Article
|
Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
|
|
Academic Article
|
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
|
|
Academic Article
|
Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.
|
|
Academic Article
|
Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
|
|
Academic Article
|
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
|
|
Academic Article
|
Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach.
|
|
Academic Article
|
Correction to Lancet Oncol 2015; 16: 747. EGFR mutations and EGFR tyrosine kinase inhibitors.
|
|
Academic Article
|
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
|
|
Academic Article
|
Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial data.
|
|
Academic Article
|
EGFR mutations and EGFR tyrosine kinase inhibitors.
|
|
Academic Article
|
Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.
|
|
Academic Article
|
LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial.
|
|
Academic Article
|
Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
|
|
Academic Article
|
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.
|
|
Academic Article
|
ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?
|
|
Academic Article
|
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.
|
|
Academic Article
|
To target or not to target, that is the question.
|
|
Academic Article
|
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
|
|
Academic Article
|
First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.
|
|
Academic Article
|
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
|
|
Academic Article
|
Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?
|
|
Academic Article
|
Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.
|
|
Academic Article
|
G48A, a New KRAS Mutation Found in Lung Adenocarcinoma.
|
|
Academic Article
|
Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
|
|
Academic Article
|
Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review.
|
|
Academic Article
|
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
|
|
Academic Article
|
Targeting the MET gene for the treatment of non-small-cell lung cancer.
|
|
Academic Article
|
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
|
|
Academic Article
|
Afatinib for lung cancer: let there be light?
|
|
Academic Article
|
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.
|
|
Academic Article
|
Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet.
|
|
Academic Article
|
Recurrent thrombosis followed by Lazarus response in ROS1 rearranged NSCLC treated with crizotinib: a case report.
|
|
Academic Article
|
LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors.
|
|
Academic Article
|
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
|
|
Academic Article
|
LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments.
|
|
Academic Article
|
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors.
|
|
Academic Article
|
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
|
|
Academic Article
|
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.
|
|
Academic Article
|
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.
|
|
Academic Article
|
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
|
|
Academic Article
|
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).
|
|
Academic Article
|
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
|
|
Academic Article
|
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.
|